Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rep. Lynch Pushes PBM Transparency Bill For Federal Benefits; OPM Resists

Executive Summary

Congressional efforts to mandate transparency rules for pharmacy benefit managers working in the Federal Employees Health Benefits Program are meeting with some resistance from top officials at the Office of Personnel Management, the agency that oversees FEHBP

You may also be interested in...

PBMs Are Focus Of Continuing Congressional Pressure For More Regulatory Oversight

Reps. Braley and Welch ask Energy and Commerce Committee Chairman Waxman and subcommittee chairmen to hold hearing on regulating pharmacy benefit managers.

NCPA Seeks To Push PBM Transparency With Momentum From Health Reform

Community pharmacy group lobbies for more co-sponsors for a recently introduced bill to expand upon reform's transparency provisions.

FTC Investigating CVS Caremark Business Practices

A campaign orchestrated by the National Community Pharmacists Association to have the Federal Trade Commission investigate the business practices of CVS Caremark has borne fruit: the company says it is under investigation

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts